About Torque

Torque is developing a new class of Deep-Primed™ immune cell therapeutics to dramatically expand cell therapy cures for cancer.

Our technology platform anchors powerful biotherapeutics—stimulatory cytokines, antibodies, and small molecules—directly to multi-target T cells to direct immune power locally in the tumor microenvironment, with pharmacologic control.

We have completed preclinical studies with our initial clinical candidate—Deep IL-15—that demonstrate increased T cell proliferation, engraftment, and tumor cell killing, including the potential to improve on pre-conditioning regimens. We will initiate the first clinical trials of Deep IL-15 in 2018.

Torque Deep-Primed cell therapeutics have the potential to be foundational therapy for both solid and hematologic tumors, addressing the two fundamental  challenges confronting immunotherapy:

  1. Immunosuppressive tumor microenvironments that limit T cell function, persistence, and trafficking
  2. Tumors with heterogeneous antigens that readily develop resistance to treatments

For both hematologic and solid tumors, our technology has the potential to improve on the initial success of CAR T therapeutics by stimulating a full immune response against tumors with heterogenous antigens that are protected by hostile microenvironments.

Back to Top